07:00 , May 20, 2013 |  BC Week In Review  |  Clinical News

ArteFill: Phase III data

A double-blind, U.S. Phase III trial in about 177 patients with moderate to severe atrophic acne scars showed that ArteFill met the primary endpoint of a greater response rate, defined as a 2-point improvement on...
08:00 , Nov 17, 2008 |  BC Week In Review  |  Company News

Artes dermatology news

Artes hired JMP Securities LLC to explore strategic alternatives while the company continues to seek equity and debt transactions to raise money. Artes markets ArteFill, polymethylmethacrylate (PMMA) microspheres suspended in ultra-purified U.S. bovine ...
07:00 , Oct 27, 2008 |  BC Week In Review  |  Clinical News

ArteFill: Post-marketing study completed enrollment

Artes completed enrollment of 1,000 patients in a 5-year, U.S. post-marketing study of ArteFill. The product was approved for the indication by FDA in October 2006. Artes Medical Inc. (NASDAQ:ARTE), San Diego, Calif.   Product: ...
07:00 , Jul 14, 2008 |  BC Week In Review  |  Company News

Anika, Artes sales and marketing update

Artes will exclusively distribute Anika's Elevess in the U.S. The hyaluronic acid-based injectable temporary dermal filler with lidocaine is used to treat facial wrinkles. Artes will sell and market the product to dermatologists, plastic...
07:00 , Jun 16, 2008 |  BC Week In Review  |  Clinical News

ArteColl update

Researchers began a U.S. clinical trial in 10 patients to compare ArteFill injected subdermally throughout the metatarsal area of 1 foot vs. no treatment in the other foot. The study is being sponsored by Artes....
07:00 , Jun 18, 2007 |  BC Week In Review  |  Company News

Artes genitourinary, gastrointestinal news

ARTE created a new subsidiary, Spheris Medical Inc., to develop and commercialize medical applications of ARTE's polymethylmethacrylate (PMMA) microspheres suspended in ultra-purified bovine collagen. The technology is in preclinical testing to bulk the esophageal...